The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of radiomics of metastatic lesions in gastroesophageal adenocarcinoma (GEA) with tumoral DKK1 mRNA expression and other immune biomarkers in patients (pts) treated with DKN-01.
 
Cynthia A. Sirard
Employment - Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Pending patent application;Application No. 62/260,959; Pending patent application;Application No. 62/260,959; Pending patent application;Application No. 62/260,959; Pending patent application;Application No. 62/260,959
Travel, Accommodations, Expenses - Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
 
Samuel J. Klempner
Stock and Other Ownership Interests - TP Therapeutics; TP Therapeutics; TP Therapeutics; TP Therapeutics
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Lilly; Lilly; Lilly; Lilly
Speakers' Bureau - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst)
 
Girish S. Naik
Employment - Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
Travel, Accommodations, Expenses - Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
 
Michael Kagey
Employment - Biogen (I); Biogen (I); Biogen (I); Biogen (I); Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics
Stock and Other Ownership Interests - Syros Pharmaceuticals; Syros Pharmaceuticals; Syros Pharmaceuticals; Syros Pharmaceuticals
Consulting or Advisory Role - Medical Research Commercialisation Fund; Medical Research Commercialisation Fund; Medical Research Commercialisation Fund; Medical Research Commercialisation Fund
Patents, Royalties, Other Intellectual Property - I have patents pending and granted for discovery based work at Leap Therapeutics (current employer), Tensha Therapeutics (acquired by Roche) and the Whitehead Institute (licensed to Syros Pharmaceuticals); I have patents pending and granted for discovery based work at Leap Therapeutics (current employer), Tensha Therapeutics (acquired by Roche) and the Whitehead Institute (licensed to Syros Pharmaceuticals); I have patents pending and granted for discovery based work at Leap Therapeutics (current employer), Tensha Therapeutics (acquired by Roche) and the Whitehead Institute (licensed to Syros Pharmaceuticals); I have patents pending and granted for discovery based work at Leap Therapeutics (current employer), Tensha Therapeutics (acquired by Roche) and the Whitehead Institute (licensed to Syros Pharmaceuticals)
 
Zak Nolte
No Relationships to Disclose
 
Ziad Hindosh
No Relationships to Disclose
 
Andre Burkett
Employment - Imaging Endpoints; Imaging Endpoints; Imaging Endpoints; Imaging Endpoints; Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I)
Leadership - Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I)
Stock and Other Ownership Interests - Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I)
Patents, Royalties, Other Intellectual Property - Imaging Endpoints; Imaging Endpoints; Imaging Endpoints; Imaging Endpoints; Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I); Imaging Endpoints (I)
 
Ronald Lee Korn
Employment - Imaging Endpoints; Imaging Endpoints; Imaging Endpoints; Imaging Endpoints
Stock and Other Ownership Interests - Globavir; Globavir; Globavir; Globavir; Teladoc; Teladoc; Teladoc; Teladoc
Consulting or Advisory Role - Dracen; Dracen; Dracen; Dracen; ImaginAB; ImaginAB; ImaginAB; ImaginAB
Research Funding - Tyme; Tyme; Tyme; Tyme
Patents, Royalties, Other Intellectual Property - Determination of Breast Cancer Malignancy using Textural analysis; Determination of Breast Cancer Malignancy using Textural analysis; Determination of Breast Cancer Malignancy using Textural analysis; Determination of Breast Cancer Malignancy using Textural analysis
Travel, Accommodations, Expenses - Deciphera; Deciphera; Deciphera; Deciphera; ImaginAb; ImaginAb; ImaginAb; ImaginAb; Kite/Gilead; Kite/Gilead; Kite/Gilead; Kite/Gilead